Inflammatory and Immune-Mediated Dermatologic Disorders Research RFP: Early Career Investigators

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

The intent of this Request for Proposal (RFP) is to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders. In particular, Pfizer has interest in alopecia areata (AA) and atopic dermatitis (AD), although other inflammatory skin conditions may be considered.

Full Proposal due date: February 24, 2022

Agency Website

Eligibility Requirements

Geographic Scope United States

To be eligible: • The institution and principal investigator (PI) must be based in the US • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Early Career is defined as an investigator that is less than 10 years past their terminal training. • Applicant must be affiliated with a host institution.



Amount Description

Individual projects requesting up to $175,000 will be considered.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 24, 2022